Mural Oncology to Join Major Investor Conferences
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two significant investor conferences where they will engage with stakeholders through presentations and one-on-one meetings. The management team, including key executives, will present insights on the company's novel, investigational engineered cytokine therapies aimed at addressing unmet medical needs in the oncology field.
Upcoming Conferences
At the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference, Caroline Loew, Ph.D., the CEO, will participate in a fireside chat alongside Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer. This engaging session is scheduled for Friday, September 6, at 1:50 p.m. ET.
H.C. Wainwright 26th Annual Global Investment Conference
Mural Oncology will also be participating in the H.C. Wainwright 26th Annual Global Investment Conference, where a presentation by CEO Caroline Loew, Ph.D., will showcase the company's advancements and visions. This presentation is set for Wednesday, September 11, at 9:30 a.m. ET.
About Mural Oncology
Mural Oncology is at the forefront of developing innovative immunotherapies leveraging its state-of-the-art protein engineering platform. The organization combines extensive expertise in cytokine biology and immune cell modulation to create treatments that offer significant clinical benefits for patients battling cancer. Their lead candidate, nemvaleukin, is advancing in potentially registrational trials focused on mucosal melanoma and platinum-resistant ovarian cancer.
Mission and Vision
The mission of Mural Oncology is clear: to expand the potential and reach of cytokine-based immunotherapies, ultimately improving the quality of life for cancer patients. The commitment to cutting-edge research and development positions Mural Oncology as a leader in the fight against cancer.
Corporate Information
The registered office of Mural Oncology is located in Dublin, Ireland, while the primary facilities are based in Waltham, Massachusetts. The company’s ongoing efforts in oncology research reflect their dedication to patient care and innovative treatment options.
Contact Information
For further inquiries, please contact:
Katie Sullivan
Email: katie.sullivan@muraloncology.com
Frequently Asked Questions
What is the focus of Mural Oncology?
Mural Oncology focuses on developing novel immuno-oncology therapies aimed at treating various types of cancer, using engineered cytokines.
What are the dates of the upcoming conferences?
The Morgan Stanley Annual Global Healthcare Conference is on September 6, and the H.C. Wainwright Annual Global Investment Conference is on September 11.
Who will be presenting on behalf of Mural Oncology?
Presentations will be made by Caroline Loew, Ph.D., CEO, along with other key management team members.
What is nemvaleukin?
Nemvaleukin is Mural Oncology's lead candidate, currently being tested in clinical trials for its effectiveness against mucosal melanoma and platinum-resistant ovarian cancer.
How can I learn more about Mural Oncology?
For more information, visit Mural Oncology’s website or follow the company on their LinkedIn and X profiles.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- INVL Technology Announces Investor Presentation and Updates
- Midland Air Conditioning Completes Major Project with Pioneer Group
- Kevin Harrington Endorses SEO Affiliate Domination Course
- Peer-to-Peer Lending Market Forecast: USD 30.54 Billion Growth
- Automated Test Equipment Market Growth Insights and Trends
- VRF Systems Market Growth Expected to Reach USD 73.88 Billion
- Automated Guided Vehicle Market Growth and Trends
- UPCX Becomes Platinum Sponsor at WebX2024 in Tokyo
- Ibotta Plans Participation in Major Investor Conferences
- ibex Appoints Andreas Wilkens as New CTO